Currently Viewing:
North American Neuroendocrine Tumor Society Symposium 2018
Dr Thorvardur Halfdanarson on Diagnostics in NETs
November 08, 2018
Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs
November 06, 2018
Currently Reading
Dr Heloisa Soares on Barriers to Achieving Positive Outcomes in NETs, What's in Store for the Future
November 01, 2018
Dr Scott Paulson on Standard of Treatment, Novel Approaches Being Taken in GEP-NETs
October 19, 2018
Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs
October 17, 2018
Research at NANETS Cites Value of Genetic Testing in Neuroendocrine Tumors
October 07, 2018
A Comprehensive Look at Updates, Developments in NETs
October 07, 2018
An Update on Lung NET Guidelines
October 07, 2018
Dr Thorvardur Halfdanarson Outlines New, Exciting Developments in Treatment of NETs
October 07, 2018
Sequencing of Lanreotide Can Improve Outcomes in Patients With Advanced GEP-NETs
October 06, 2018
Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape
October 06, 2018
Merkel Cell Carcinoma in the United States: Prognostics and Treatment Options
October 06, 2018
Debating Best First-Line Treatment in Well-Differentiated G3 NENs
October 06, 2018
Examining the Benefits of Integrative Oncology, Nutrition in NETs
October 05, 2018
Dr Heloisa Soares Discusses the Roles of Somatostatin Analogs in GEP-NETs
October 05, 2018
Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs
October 05, 2018
Measuring Quality of Life Among Patients With Neuroendocrine Tumors
October 05, 2018

Dr Heloisa Soares on Barriers to Achieving Positive Outcomes in NETs, What's in Store for the Future

Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, outlines current barriers to achieving positive outcomes in neuroendocrine tumors (NETs) and what's in store for the future.


Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, outlines current barriers to achieving positive outcomes in neuroendocrine tumors (NETs) and what's in store for the future.

Transcript

What are the biggest barriers to achieving positive outcomes in neuroendocrine tumors?

I think there are a few issues that we have to think of. Number one, patients are diagnosed rather late in the game, so by the time of diagnosis, most patients are already in stage 4 metastatic disease, so the chances of actually curing the disease are much less. We also can do a much better job in terms of paraclinical science. You know, neuroendocrine tumors are very challenging for paraclinical in vitro models, mice models, and things like that. So, once we develop more of that, I think it will be easier to translate research to the bedside.  

And then, finally, I think we know we certainly need more attention from funding resources to focus on giving more research money and support for neuroendocrine tumor research so more scientists and physicians can focus on that. I think if we some of this taken care of, I think the advances in neuroendocrine tumor research would be upcoming.

What’s in the future for the treatment of neuroendocrine tumors?

I think just stay tuned for the new therapies that are coming up. There is an exciting trial coming up with cabozantinib. It’s a phase 3 trial that will hopefully give us another option of therapy for patients. If this trial ends up being positive, I think we should look forward to the results of this, which might take several years to come. But, I would encourage patients, if they were given the opportunity to consider participation on this trial, to do so because I think it’s an important trial.

We are also going to be hearing about several trials talking probably about sequencing of treatment in the era of peptide receptor radionuclide therapy (PRRT), and we don’t know the right sequence of treatment right now with PRRT, and I think the trials that are being designed and will be conducted in the near future will be very important to help us guide this a little bit more.

                                      

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!